Report Detail

Pharma & Healthcare Global Antihyperlipidemic Drug Market Growth (Status and Outlook) 2022-2028

  • RnM4495543
  • |
  • 24 November, 2022
  • |
  • Global
  • |
  • 104 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

Lipids are chemical substances that are insoluble in water such as cholesterol and triglycerides. Hyperlipidemia is a medical condition marked by elevation of lipid level in the blood. This rise in lipid levels leads to increase in fatty deposits in arteries, which cause blockages in the arteries of the patient. The blockages can in turn lead to rise in risk related to heart attacks. Therefore, hyperlipidemia is a major medical condition that requires treatment. The drugs that are used to treat hyperlipidemia are called as antihyperlipidemic drugs. Some of the drugs available in the market include bile acid, sequestrants, cholesterol absorption inhibitors, and others.
The global market for Antihyperlipidemic Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Antihyperlipidemic Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Antihyperlipidemic Drug players cover Sanofi, Boehringer Ingelheim, Merck KGaA, Johnson and Johnson and Bayer AG, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Antihyperlipidemic Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Antihyperlipidemic Drug market, with both quantitative and qualitative data, to help readers understand how the Antihyperlipidemic Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the Antihyperlipidemic Drug market and forecasts the market size by Type (Statins, PCSK9 Inhibitors and Bile Acid Chelators), by Application (Hospital Pharmacy, Online Pharmacy, Clinics and Others), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Statins
PCSK9 Inhibitors
Bile Acid Chelators
Cholesterol Absorption Inhibitors
Others

Segmentation by application
Hospital Pharmacy
Online Pharmacy
Clinics
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Sanofi
Boehringer Ingelheim
Merck KGaA
Johnson and Johnson
Bayer AG
Pfizer
Takeda Pharmaceutical Co
AstraZeneca
Daiichi Sankyo
Novartis International AG
AbbVie
Amgen
Bristol Myers Squibb

Chapter Introduction
Chapter 1: Scope of Antihyperlipidemic Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Antihyperlipidemic Drug market size and CAGR, Antihyperlipidemic Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Antihyperlipidemic Drug revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Antihyperlipidemic Drug revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Antihyperlipidemic Drug market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi, Boehringer Ingelheim, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Takeda Pharmaceutical Co, AstraZeneca and Daiichi Sankyo, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Antihyperlipidemic Drug Market Size 2017-2028
    • 2.1.2 Antihyperlipidemic Drug Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Antihyperlipidemic Drug Segment by Type
    • 2.2.1 Statins
    • 2.2.2 PCSK9 Inhibitors
    • 2.2.3 Bile Acid Chelators
    • 2.2.4 Cholesterol Absorption Inhibitors
    • 2.2.5 Others
  • 2.3 Antihyperlipidemic Drug Market Size by Type
    • 2.3.1 Antihyperlipidemic Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Antihyperlipidemic Drug Market Size Market Share by Type (2017-2022)
  • 2.4 Antihyperlipidemic Drug Segment by Application
    • 2.4.1 Hospital Pharmacy
    • 2.4.2 Online Pharmacy
    • 2.4.3 Clinics
    • 2.4.4 Others
  • 2.5 Antihyperlipidemic Drug Market Size by Application
    • 2.5.1 Antihyperlipidemic Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Antihyperlipidemic Drug Market Size Market Share by Application (2017-2022)

3 Antihyperlipidemic Drug Market Size by Player

  • 3.1 Antihyperlipidemic Drug Market Size Market Share by Players
    • 3.1.1 Global Antihyperlipidemic Drug Revenue by Players (2020-2022)
    • 3.1.2 Global Antihyperlipidemic Drug Revenue Market Share by Players (2020-2022)
  • 3.2 Global Antihyperlipidemic Drug Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Antihyperlipidemic Drug by Regions

  • 4.1 Antihyperlipidemic Drug Market Size by Regions (2017-2022)
  • 4.2 Americas Antihyperlipidemic Drug Market Size Growth (2017-2022)
  • 4.3 APAC Antihyperlipidemic Drug Market Size Growth (2017-2022)
  • 4.4 Europe Antihyperlipidemic Drug Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Antihyperlipidemic Drug Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Antihyperlipidemic Drug Market Size by Country (2017-2022)
  • 5.2 Americas Antihyperlipidemic Drug Market Size by Type (2017-2022)
  • 5.3 Americas Antihyperlipidemic Drug Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Antihyperlipidemic Drug Market Size by Region (2017-2022)
  • 6.2 APAC Antihyperlipidemic Drug Market Size by Type (2017-2022)
  • 6.3 APAC Antihyperlipidemic Drug Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Antihyperlipidemic Drug by Country (2017-2022)
  • 7.2 Europe Antihyperlipidemic Drug Market Size by Type (2017-2022)
  • 7.3 Europe Antihyperlipidemic Drug Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Antihyperlipidemic Drug by Region (2017-2022)
  • 8.2 Middle East & Africa Antihyperlipidemic Drug Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Antihyperlipidemic Drug Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Antihyperlipidemic Drug Market Forecast

  • 10.1 Global Antihyperlipidemic Drug Forecast by Regions (2023-2028)
    • 10.1.1 Global Antihyperlipidemic Drug Forecast by Regions (2023-2028)
    • 10.1.2 Americas Antihyperlipidemic Drug Forecast
    • 10.1.3 APAC Antihyperlipidemic Drug Forecast
    • 10.1.4 Europe Antihyperlipidemic Drug Forecast
    • 10.1.5 Middle East & Africa Antihyperlipidemic Drug Forecast
  • 10.2 Americas Antihyperlipidemic Drug Forecast by Country (2023-2028)
    • 10.2.1 United States Antihyperlipidemic Drug Market Forecast
    • 10.2.2 Canada Antihyperlipidemic Drug Market Forecast
    • 10.2.3 Mexico Antihyperlipidemic Drug Market Forecast
    • 10.2.4 Brazil Antihyperlipidemic Drug Market Forecast
  • 10.3 APAC Antihyperlipidemic Drug Forecast by Region (2023-2028)
    • 10.3.1 China Antihyperlipidemic Drug Market Forecast
    • 10.3.2 Japan Antihyperlipidemic Drug Market Forecast
    • 10.3.3 Korea Antihyperlipidemic Drug Market Forecast
    • 10.3.4 Southeast Asia Antihyperlipidemic Drug Market Forecast
    • 10.3.5 India Antihyperlipidemic Drug Market Forecast
    • 10.3.6 Australia Antihyperlipidemic Drug Market Forecast
  • 10.4 Europe Antihyperlipidemic Drug Forecast by Country (2023-2028)
    • 10.4.1 Germany Antihyperlipidemic Drug Market Forecast
    • 10.4.2 France Antihyperlipidemic Drug Market Forecast
    • 10.4.3 UK Antihyperlipidemic Drug Market Forecast
    • 10.4.4 Italy Antihyperlipidemic Drug Market Forecast
    • 10.4.5 Russia Antihyperlipidemic Drug Market Forecast
  • 10.5 Middle East & Africa Antihyperlipidemic Drug Forecast by Region (2023-2028)
    • 10.5.1 Egypt Antihyperlipidemic Drug Market Forecast
    • 10.5.2 South Africa Antihyperlipidemic Drug Market Forecast
    • 10.5.3 Israel Antihyperlipidemic Drug Market Forecast
    • 10.5.4 Turkey Antihyperlipidemic Drug Market Forecast
    • 10.5.5 GCC Countries Antihyperlipidemic Drug Market Forecast
  • 10.6 Global Antihyperlipidemic Drug Forecast by Type (2023-2028)
  • 10.7 Global Antihyperlipidemic Drug Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Sanofi
    • 11.1.1 Sanofi Company Information
    • 11.1.2 Sanofi Antihyperlipidemic Drug Product Offered
    • 11.1.3 Sanofi Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Sanofi Main Business Overview
    • 11.1.5 Sanofi Latest Developments
  • 11.2 Boehringer Ingelheim
    • 11.2.1 Boehringer Ingelheim Company Information
    • 11.2.2 Boehringer Ingelheim Antihyperlipidemic Drug Product Offered
    • 11.2.3 Boehringer Ingelheim Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Boehringer Ingelheim Main Business Overview
    • 11.2.5 Boehringer Ingelheim Latest Developments
  • 11.3 Merck KGaA
    • 11.3.1 Merck KGaA Company Information
    • 11.3.2 Merck KGaA Antihyperlipidemic Drug Product Offered
    • 11.3.3 Merck KGaA Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 Merck KGaA Main Business Overview
    • 11.3.5 Merck KGaA Latest Developments
  • 11.4 Johnson and Johnson
    • 11.4.1 Johnson and Johnson Company Information
    • 11.4.2 Johnson and Johnson Antihyperlipidemic Drug Product Offered
    • 11.4.3 Johnson and Johnson Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Johnson and Johnson Main Business Overview
    • 11.4.5 Johnson and Johnson Latest Developments
  • 11.5 Bayer AG
    • 11.5.1 Bayer AG Company Information
    • 11.5.2 Bayer AG Antihyperlipidemic Drug Product Offered
    • 11.5.3 Bayer AG Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Bayer AG Main Business Overview
    • 11.5.5 Bayer AG Latest Developments
  • 11.6 Pfizer
    • 11.6.1 Pfizer Company Information
    • 11.6.2 Pfizer Antihyperlipidemic Drug Product Offered
    • 11.6.3 Pfizer Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Pfizer Main Business Overview
    • 11.6.5 Pfizer Latest Developments
  • 11.7 Takeda Pharmaceutical Co
    • 11.7.1 Takeda Pharmaceutical Co Company Information
    • 11.7.2 Takeda Pharmaceutical Co Antihyperlipidemic Drug Product Offered
    • 11.7.3 Takeda Pharmaceutical Co Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Takeda Pharmaceutical Co Main Business Overview
    • 11.7.5 Takeda Pharmaceutical Co Latest Developments
  • 11.8 AstraZeneca
    • 11.8.1 AstraZeneca Company Information
    • 11.8.2 AstraZeneca Antihyperlipidemic Drug Product Offered
    • 11.8.3 AstraZeneca Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 AstraZeneca Main Business Overview
    • 11.8.5 AstraZeneca Latest Developments
  • 11.9 Daiichi Sankyo
    • 11.9.1 Daiichi Sankyo Company Information
    • 11.9.2 Daiichi Sankyo Antihyperlipidemic Drug Product Offered
    • 11.9.3 Daiichi Sankyo Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 Daiichi Sankyo Main Business Overview
    • 11.9.5 Daiichi Sankyo Latest Developments
  • 11.10 Novartis International AG
    • 11.10.1 Novartis International AG Company Information
    • 11.10.2 Novartis International AG Antihyperlipidemic Drug Product Offered
    • 11.10.3 Novartis International AG Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 Novartis International AG Main Business Overview
    • 11.10.5 Novartis International AG Latest Developments
  • 11.11 AbbVie
    • 11.11.1 AbbVie Company Information
    • 11.11.2 AbbVie Antihyperlipidemic Drug Product Offered
    • 11.11.3 AbbVie Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.11.4 AbbVie Main Business Overview
    • 11.11.5 AbbVie Latest Developments
  • 11.12 Amgen
    • 11.12.1 Amgen Company Information
    • 11.12.2 Amgen Antihyperlipidemic Drug Product Offered
    • 11.12.3 Amgen Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.12.4 Amgen Main Business Overview
    • 11.12.5 Amgen Latest Developments
  • 11.13 Bristol Myers Squibb
    • 11.13.1 Bristol Myers Squibb Company Information
    • 11.13.2 Bristol Myers Squibb Antihyperlipidemic Drug Product Offered
    • 11.13.3 Bristol Myers Squibb Antihyperlipidemic Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.13.4 Bristol Myers Squibb Main Business Overview
    • 11.13.5 Bristol Myers Squibb Latest Developments

12 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Antihyperlipidemic Drug. Industry analysis & Market Report on Antihyperlipidemic Drug is a syndicated market report, published as Global Antihyperlipidemic Drug Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Antihyperlipidemic Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,045.12
6,090.24
3,528.24
7,056.48
507,202.80
1,014,405.60
298,399.80
596,799.60
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report